Calidi Biotherapeutics (CLDI) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.84, -3.79% vs the prior close of $0.87.
- Volume 35.09K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CLDI slides 3.8% to $0.84, a 52-week low, 6 down days in a row. Closed at $0.84, -3.79% vs the prior close of $0.87. Day range $0.80–$0.89, opened at $0.89.
CLDI daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CLDI slides 3.8% to $0.84, a 52-week low, 6 down days in a row
- Closed at $0.84, -3.79% vs the prior close of $0.87. Day range $0.80–$0.89, opened at $0.89.
- Volume was 35.09K shares, 0.2x its 50-day average of 146.57K — lighter than usual.
- Price is -32.0% vs its 50-day average ($1.23) and -84.3% vs its 200-day average ($5.32).
- 52-week range $0.80–$27.20; today's close sits at 0% of that range, 96.9% below the 52-week high.
- That makes 6 straight losses.
Oct 15, 2026 — CLDI dips 0.5% to $0.87, a 52-week low, 5 down days in a row
- Closed at $0.87, -0.46% vs the prior close of $0.87. Day range $0.86–$0.89, opened at $0.87.
- Volume was 23.80K shares, 0.2x its 50-day average of 149.51K — lighter than usual.
- Price is -30.4% vs its 50-day average ($1.25) and -83.9% vs its 200-day average ($5.41).
- 52-week range $0.82–$27.84; today's close sits at 0% of that range, 96.9% below the 52-week high.
- That makes 5 straight losses.
Oct 14, 2026 — CLDI dips 2.9% to $0.87, a 52-week low, 4 down days in a row
- Closed at $0.87, -2.89% vs the prior close of $0.90. Day range $0.82–$0.92, opened at $0.90.
- Volume was 52.80K shares, 0.3x its 50-day average of 153.97K — lighter than usual.
- Price is -31.1% vs its 50-day average ($1.27) and -84.1% vs its 200-day average ($5.50).
- 52-week range $0.82–$27.84; today's close sits at 0% of that range, 96.9% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — CLDI slides 5.3% to $0.90, a 52-week low, 3 down days in a row
- Closed at $0.90, -5.26% vs the prior close of $0.95. Day range $0.87–$0.93, opened at $0.93.
- Volume was 63.80K shares, 0.4x its 50-day average of 157.98K — lighter than usual.
- Price is -30.1% vs its 50-day average ($1.29) and -83.9% vs its 200-day average ($5.59).
- 52-week range $0.87–$27.84; today's close sits at 0% of that range, 96.8% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — CLDI slides 7.8% to $0.95, a 52-week low
- Closed at $0.95, -7.77% vs the prior close of $1.03. Day range $0.94–$1.00, opened at $1.00.
- Volume was 52.60K shares, 0.3x its 50-day average of 166.22K — lighter than usual.
- Price is -27.1% vs its 50-day average ($1.30) and -83.3% vs its 200-day average ($5.69).
- 52-week range $0.94–$27.84; today's close sits at 0% of that range, 96.6% below the 52-week high.
Oct 9, 2026 — CLDI dips 1.0% to $1.03
- Closed at $1.03, -0.96% vs the prior close of $1.04. Day range $1.03–$1.05, opened at $1.04.
- Volume was 18.00K shares, 0.1x its 50-day average of 165.86K — lighter than usual.
- Price is -21.8% vs its 50-day average ($1.32) and -82.2% vs its 200-day average ($5.79).
- 52-week range $0.99–$27.84; today's close sits at 0% of that range, 96.3% below the 52-week high.
Oct 8, 2026 — CLDI rises 3.0% to $1.04
- Closed at $1.04, +2.97% vs the prior close of $1.01. Day range $1.00–$1.04, opened at $1.02.
- Volume was 18.20K shares, 0.1x its 50-day average of 168.43K — lighter than usual.
- Price is -21.6% vs its 50-day average ($1.33) and -82.4% vs its 200-day average ($5.90).
- 52-week range $0.99–$27.84; today's close sits at 0% of that range, 96.3% below the 52-week high.
Oct 7, 2026 — CLDI dips 1.0% to $1.01, a 52-week low, 4 down days in a row
- Closed at $1.01, -0.98% vs the prior close of $1.02. Day range $0.99–$1.03, opened at $1.02.
- Volume was 51.50K shares, 0.3x its 50-day average of 170.58K — lighter than usual.
- Price is -24.4% vs its 50-day average ($1.34) and -83.2% vs its 200-day average ($6.00).
- 52-week range $0.99–$27.84; today's close sits at 0% of that range, 96.4% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — CLDI dips 2.9% to $1.02, a 52-week low, 3 down days in a row
- Closed at $1.02, -2.86% vs the prior close of $1.05. Day range $1.00–$1.07, opened at $1.06.
- Volume was 71.70K shares, 0.4x its 50-day average of 178.40K — lighter than usual.
- Price is -24.4% vs its 50-day average ($1.35) and -83.3% vs its 200-day average ($6.10).
- 52-week range $1.00–$27.84; today's close sits at 0% of that range, 96.3% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — CLDI dips 2.8% to $1.05, a 52-week low
- Closed at $1.05, -2.78% vs the prior close of $1.08. Day range $1.00–$1.12, opened at $1.08.
- Volume was 22.00K shares, 0.1x its 50-day average of 228.13K — lighter than usual.
- Price is -23.0% vs its 50-day average ($1.36) and -83.1% vs its 200-day average ($6.20).
- 52-week range $1.00–$27.84; today's close sits at 0% of that range, 96.2% below the 52-week high.
Oct 2, 2026 — CLDI ends flat (+0.0%) to $1.08
- Closed at $1.08, +0.00% vs the prior close of $1.08. Day range $1.05–$1.09, opened at $1.09.
- Volume was 38.60K shares, 0.1x its 50-day average of 294.84K — lighter than usual.
- Price is -21.5% vs its 50-day average ($1.38) and -82.8% vs its 200-day average ($6.29).
- 52-week range $1.03–$27.84; today's close sits at 0% of that range, 96.1% below the 52-week high.
CLDI latest news & SEC filings
Every SEC filing by or about CLDI in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
- Item 8.01 — Reported other events the company considers important.
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Sep 17, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$4.16M (prior year -$5.71M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$2.94 (prior year -$31.75) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade CLDI
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 27, 2026, Jan 29, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.89% (largest 10.1%).
- Liquidity: about 218.96K shares (≈$183.27K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.84 vs a range of $0.80–$27.20 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:16 on Jul 31, 2026, 1:12 on Aug 5, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Allan Camaisa sold 850 shares on Dec 12, 2025.
- Latest filings: 8-K Sep 25, 2026; 8-K Sep 22, 2026; 10-Q Aug 13, 2026.
- Share count: 2.58M shares outstanding (Aug 10, 2026), -24.6% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Biological Products, (No Diagnostic Substances).
CLDI market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.89 | 0.89 | 0.80 | 0.84 | 35.09K |
| Oct 15, 2026 | 0.87 | 0.89 | 0.86 | 0.87 | 23.80K |
| Oct 14, 2026 | 0.90 | 0.92 | 0.82 | 0.87 | 52.80K |
| Oct 13, 2026 | 0.93 | 0.93 | 0.87 | 0.90 | 63.80K |
| Oct 12, 2026 | 1.00 | 1.00 | 0.94 | 0.95 | 52.60K |
| Oct 9, 2026 | 1.04 | 1.05 | 1.03 | 1.03 | 18.00K |
| Oct 8, 2026 | 1.02 | 1.04 | 1.00 | 1.04 | 18.20K |
| Oct 7, 2026 | 1.02 | 1.03 | 0.99 | 1.01 | 51.50K |
| Oct 6, 2026 | 1.06 | 1.07 | 1.00 | 1.02 | 71.70K |
| Oct 5, 2026 | 1.08 | 1.12 | 1.00 | 1.05 | 22.00K |
| Oct 2, 2026 | 1.09 | 1.09 | 1.05 | 1.08 | 38.60K |
| Oct 1, 2026 | 1.07 | 1.08 | 1.05 | 1.08 | 14.90K |
| Sep 30, 2026 | 1.08 | 1.10 | 1.05 | 1.07 | 48.90K |
| Sep 29, 2026 | 1.08 | 1.08 | 1.03 | 1.08 | 43.20K |
| Sep 28, 2026 | 1.10 | 1.13 | 1.05 | 1.07 | 154.50K |
| Sep 25, 2026 | 1.20 | 1.29 | 1.13 | 1.13 | 128.60K |
| Sep 24, 2026 | 1.15 | 1.25 | 1.10 | 1.20 | 587.80K |
| Sep 23, 2026 | 1.10 | 1.15 | 1.05 | 1.09 | 2.88M |
| Sep 22, 2026 | 1.11 | 1.15 | 1.11 | 1.11 | 37.10K |
| Sep 21, 2026 | 1.11 | 1.16 | 1.10 | 1.11 | 33.40K |
About Calidi Biotherapeutics
Calidi Biotherapeutics (CLDI) is listed on the NYSE and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1855485.
CLDI board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Allan Camaisa | Director | Dec 16, 2025 |
| Scott Leftwich | Director | Aug 19, 2026 |
| George Peoples | Director | Aug 19, 2026 |
| Corazon (Corsee) D. Sanders | Director | Aug 19, 2026 |
| James A Schoeneck | Director | Aug 19, 2026 |
| Alan R. Stewart | Director | Aug 19, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Santidrian Antonio Fernandez | Chief Scientific Officer | Aug 19, 2026 |
| Andrew C. Jackson | Chief Financial Officer | Aug 19, 2026 |
| Eric E Poma | Chief Executive Officer | Aug 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 12, 2025 | Allan Camaisa | Sale | 850 | $1.46 |
| Dec 12, 2025 | Allan Camaisa | Sale | 850 | $1.46 |
| Dec 12, 2025 | Allan Camaisa | Sale | 850 | $1.46 |
| Dec 12, 2025 | Allan Camaisa | Sale | 850 | $1.46 |
CLDI financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-19.91M | -5.95 | $-21.29M |
| Dec 31, 2024 | — | $-22.14M | -35.70 | $-19.69M |
| Dec 31, 2023 | — | $-29.22M | -17.33 | $-26.98M |
| Dec 31, 2022 | $45.00K | $-25.43M | 2.99 | $-13.21M |
Latest balance sheet: total assets $7.20M, total liabilities $4.07M, cash $9.60M (as of Jun 30, 2026).
CLDI earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $1.54 |
| May 14, 2026 | 8-K Item 2.02 (results) | $3.04 |
| Mar 27, 2026 | 8-K Item 2.02 (results) | $4.34 |
| Jan 29, 2026 | 8-K Item 2.02 (results) | $16.80 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $24.32 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $80.16 |
| May 14, 2025 | 8-K Item 2.02 (results) | $76.80 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $108.67 |
| Jan 28, 2025 | 8-K Item 2.02 (results) | $126.14 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $648.96 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CLDI
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.